Business
Ensysce Biosciences Initiates Review of Strategic Alternatives to Enhance Shareholder Value
Review Includes Strategic Partnerships, Licensing and Other Corporate Transactions Focused on Advancing TAAPTM and MPAR® Platforms SAN DIEGO, CALIFORNIA /
About this update from Ensysce Biosciences, Inc.
[{"type":"text","content":"Review Includes Strategic Partnerships, Licensing and Other Corporate Transactions Focused on Advancing TAAPTM and MPAR® Platforms SAN DIEGO, CALIFORNIA / ACCESS Newswire / February 25, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (\"Ensysce\" or the \"Company\"), a clinical-stage pharmaceutical company developing innovative solutions for novel therapeutics while reducing the potential for abuse and overdose, today announced its Board of Directors has initiated a formal review of a broad range of strategic alternatives intended to enhance shareholder value and support the continued advancement of the Company's proprietary technologies.Potential strategic alternatives may include, among other things, strategic partnerships, licensing arrangements, capital formation transactions, business combinations, asset sales or other corporate transactions. There can be no assurances that the review will result in any specific transaction, and the Company has not set a timetable for the completion of the review process.\"Our technologies were designed to fundamentally improve the safety profile of opioids, and we believe they have relevance well beyond a single class.\" said Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce Biosciences. \"We are thoughtfully exploring strategic alternatives that we believe could unlock additional value for our shareholders while allowing us to remain disciplined in our executionand focused on advancing our TAAP™ and MPAR® platforms.\"The Company does not intend to disclose further developments with respect to this review unless and until its Board of Directors approves a specific transaction or otherwise determines that further disclosure is appropriate or required by law.About Ensysce BiosciencesEnsysce Biosciences is a clinical-stage pharmaceutical company dedicated to disrupting the analgesic landscape through the development of a new class of safer opioid medicines for the treatment of severe pain. Leveraging its proprietary Trypsin-Activated Abuse Protection (TAAP™) and Multi-Pill Abuse Resistance (MPAR®) platforms, Ensysce is advancing tamper-resistant therapeutic options designed to minimize the risk of opioid abuse and oral overdose while preserving strong analgesic efficacy. For more information, visit www.ensysce.com.Forward-Looking StatementsStatements contained in this press release that...